166 related articles for article (PubMed ID: 15291652)
21. Economic burden of schizophrenia: empirical analyses from a survey in Thailand.
Phanthunane P; Whiteford H; Vos T; Bertram M
J Ment Health Policy Econ; 2012 Mar; 15(1):25-32. PubMed ID: 22611090
[TBL] [Abstract][Full Text] [Related]
22. Cost analysis of treating schizophrenia with amisulpride: naturalistic mirror image study.
Surguladze S; Patel A; Kerwin RW; Knapp M; Travis MJ
Prog Neuropsychopharmacol Biol Psychiatry; 2005 May; 29(4):517-22. PubMed ID: 15866352
[TBL] [Abstract][Full Text] [Related]
23. Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE).
Lieberman JA
Arch Gen Psychiatry; 2006 Oct; 63(10):1069-72. PubMed ID: 17015808
[No Abstract] [Full Text] [Related]
24. Assessing the value of antipsychotics for treating schizophrenia: the importance of evaluating and interpreting the clinical significance of individual service costs.
Tunis SL; Ascher-Svanum H; Stensland M; Kinon BJ
Pharmacoeconomics; 2004; 22(1):1-8. PubMed ID: 14720078
[TBL] [Abstract][Full Text] [Related]
25. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia.
Ascher-Svanum H; Nyhuis AW; Faries DE; Kinon BJ; Baker RW; Shekhar A
Schizophr Bull; 2008 Nov; 34(6):1163-71. PubMed ID: 18156640
[TBL] [Abstract][Full Text] [Related]
26. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia.
Gilmer TP; Dolder CR; Lacro JP; Folsom DP; Lindamer L; Garcia P; Jeste DV
Am J Psychiatry; 2004 Apr; 161(4):692-9. PubMed ID: 15056516
[TBL] [Abstract][Full Text] [Related]
27. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
Woods SW; Gueorguieva RV; Baker CB; Makuch RW
Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
[TBL] [Abstract][Full Text] [Related]
28. A retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophrenia.
Zhao Z
Manag Care Interface; 2002 Feb; 15(2):75-81. PubMed ID: 11875967
[TBL] [Abstract][Full Text] [Related]
29. Modeling of annual treatment costs and health outcomes of antipsychotic agents for schizophrenic populations. Based on a presentation by Josephine Mauskopf, PhD.
Am J Manag Care; 1999 Jul; 5(10 Suppl):S601-11. PubMed ID: 10539495
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of schizophrenia pharmacotherapy.
Soumerai SB; Law MR
Am J Psychiatry; 2007 Apr; 164(4):678; author reply 678-9. PubMed ID: 17403984
[No Abstract] [Full Text] [Related]
31. Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients.
Rascati KL; Johnsrud MT; Crismon ML; Lage MJ; Barber BL
Pharmacoeconomics; 2003; 21(10):683-97. PubMed ID: 12828491
[TBL] [Abstract][Full Text] [Related]
32. An economic review of compliance with medication therapy in the treatment of schizophrenia.
Thieda P; Beard S; Richter A; Kane J
Psychiatr Serv; 2003 Apr; 54(4):508-16. PubMed ID: 12663838
[TBL] [Abstract][Full Text] [Related]
33. Olanzapine: an updated review of its use in the management of schizophrenia.
Bhana N; Foster RH; Olney R; Plosker GL
Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
[TBL] [Abstract][Full Text] [Related]
34. Outcome in schizophrenia: beyond symptom reduction.
Meltzer HY
J Clin Psychiatry; 1999; 60 Suppl 3():3-7; discussion 8. PubMed ID: 10073370
[TBL] [Abstract][Full Text] [Related]
35. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.
Gibson PJ; Damler R; Jackson EA; Wilder T; Ramsey JL
Value Health; 2004; 7(1):22-35. PubMed ID: 14720128
[TBL] [Abstract][Full Text] [Related]
36. Outpatient antipsychotic treatment and inpatient costs of schizophrenia.
Marcus SC; Olfson M
Schizophr Bull; 2008 Jan; 34(1):173-80. PubMed ID: 17578893
[TBL] [Abstract][Full Text] [Related]
37. Does Non-Adherence Increase Treatment Costs in Schizophrenia?
Pennington M; McCrone P
Pharmacoeconomics; 2018 Aug; 36(8):941-955. PubMed ID: 29700755
[TBL] [Abstract][Full Text] [Related]
38. Impact of drug treatment history on comparative effectiveness research in schizophrenia.
McCombs J; Zolfaghari S; Ganapathy V
Value Health; 2011; 14(5):679-86. PubMed ID: 21839406
[TBL] [Abstract][Full Text] [Related]
39. Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany.
Zeidler J; Mahlich J; Greiner W; Heres S
Appl Health Econ Health Policy; 2013 Oct; 11(5):509-21. PubMed ID: 23975630
[TBL] [Abstract][Full Text] [Related]
40. Depot antipsychotic preparations in schizophrenia: the state of the economic evidence.
Knapp M; Ilson S; David A
Int Clin Psychopharmacol; 2002 May; 17(3):135-40. PubMed ID: 11981355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
